Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8807MR)

This product GTTS-WQ8807MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8807MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2099MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ5214MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ12502MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ2004MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ5362MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ8656MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ6118MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ6097MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO-1959
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW